Related Experiment Video
Updated: Jun 5, 2025
09:33
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
1.1K
Molecular profiling in MPN: who should have it and why?
Ashlyn Chee1,2, Adam J Mead1,2,3
1Cancer and Haematology Centre, Department of Clinical Haematology, The Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Hematology. American Society of Hematology. Education Program
|December 7, 2024
Summary
Molecular profiling is crucial for diagnosing and managing Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). Genetic analysis guides risk stratification and therapy response monitoring in these blood cancers.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Myeloproliferative neoplasms (MPNs) are blood cancers driven by somatic mutations in hematopoietic stem cells.
- These mutations lead to constitutive activation of JAK-STAT signaling pathways, causing myeloid lineage overproduction.
Purpose of the Study:
- To review current molecular profiling approaches for classical MPNs.
- To demonstrate the integration of genetic analysis in MPN diagnosis, risk stratification, and therapy response monitoring.
Main Methods:
- Review of current literature and clinical case histories.
- Analysis of molecular profiling techniques for essential thrombocythemia, polycythemia vera, and myelofibrosis.
Main Results:
- Molecular profiling is central to MPN diagnosis and risk stratification.
- Genetic analysis is increasingly used to monitor therapy response in clinical trials and practice.
Conclusions:
- Molecular profiling is integral to the management of MPNs.
- Future applications include guiding targeted therapies and exploring novel genetic methodologies.
